Seres Therapeutics, Inc. - MCRB STOCK NEWS

Seres Therapeutics (NASDAQ: MCRB) announced favorable results from the ECOSPOR IV study for SER-109, an oral microbiome therapy for recurrent C. difficile infection. The study showed a 91.3% sustained clinical response at eight weeks and confirmed a favorable safety profile, consistent with the previous ECOSPOR III study. A rolling Biologics License Application (BLA) submission has been initiated, with completion anticipated by mid-2022. The company aims for a potential launch in the first half of 2023, supported by FDA Breakthrough Therapy designation.

Seres Therapeutics, Inc. (MCRB) presented preclinical data highlighting the efficacy of the investigational microbial consortium DE486 in reducing chemotherapy-induced mucositis. The findings will be discussed at the 2022 ASCO Annual Meeting. Additionally, a Phase 1b trial of SER-155 is being conducted to assess its safety and efficacy in preventing complications during stem cell transplants. The company also plans to present Phase III results of SER-109 for recurrent C. difficile infection, which showed a lower recurrence rate than placebo. SER-109 is expected to submit a BLA to the FDA in mid-2022.

Seres Therapeutics, Inc. (Nasdaq: MCRB) presented promising data from its Phase 3 ECOSPOR III study, demonstrating that SER-109 effectively prevents recurrent C. difficile infections by establishing beneficial gut microbes. After one week of treatment, SER-109 increased microbiome diversity, producing fatty acids that inhibit C. difficile growth. The therapy showed an 88% success rate in preventing infection recurrence at eight weeks. Seres aims to submit a Biologics License Application by mid-2022, potentially leading to the first FDA-approved microbiome therapeutic by early 2023.

Seres Therapeutics (Nasdaq: MCRB) announced the presentation of its ECOSPOR III trial data for SER-109 at the Digestive Disease Week (DDW) Annual Meeting, scheduled for May 21-24, 2022. SER-109 is an investigational oral microbiome therapy aimed at preventing recurrent C. difficile infections. The company plans to submit a Biologics License Application (BLA) to the FDA in mid-2022. Presentations include an oral session on SER-109's impact on stool fatty acid metabolites and a poster on its durable engraftment. SER-109 has FDA Breakthrough and Orphan Drug designations.

Seres Therapeutics reported Q1 2022 results, highlighting significant progress with SER-109 for recurrent C. difficile infection (rCDI). The FDA approved a rolling submission for the Biologics License Application (BLA), targeting completion by mid-2022. SER-109 demonstrated superior efficacy with 88% of patients achieving sustained responses. The company faced a net loss of $56.6 million, an increase from $35.5 million the previous year, primarily driven by rising R&D costs. Seres ended the quarter with $248 million in cash, down from $291 million at the end of 2021, indicating potential cash burn risks.

Seres Therapeutics, Inc. (NASDAQ: MCRB) announced a conference call on May 4, 2022, at 8:30 a.m. ET to discuss its first quarter results and provide a business update. The call can be accessed by dialing 877-270-2148 (domestic) or 412-902-6510 (international). The company is known for its innovative microbiome therapeutics, particularly the SER-109 program, which has received Breakthrough Therapy and Orphan Drug designations from the FDA. SER-109 aims to reduce C. difficile infection recurrence, marking a significant milestone in microbiome-based treatments.

Seres Therapeutics (Nasdaq: MCRB) presents promising preclinical data on SER-155 at the European Bone Marrow Transplantation Annual Meeting. The findings indicate that SER-155 can potentially reduce infections and Graft-versus-Host Disease (GvHD) in patients undergoing hematopoietic stem cell transplantation. The ongoing Phase 1b clinical trial aims to evaluate SER-155's safety and efficacy after vancomycin treatment. Preliminary results show SER-155 enhances gut immunity and may restore a healthy microbiome, addressing a critical need in transplant recovery.

Seres Therapeutics (Nasdaq: MCRB) will present at the 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022, at 8:00 a.m. ET, by CEO Eric Shaff. An audio webcast will be accessible via the Investors section of their website, with a replay available one hour post-event for 21 days. Seres is recognized for its SER-109 program, targeting recurrent C. difficile infections, which received Breakthrough Therapy and Orphan Drug designations from the FDA. The firm is also advancing SER-301 and SER-155 in clinical trials for ulcerative colitis and gastrointestinal infections respectively.

Seres Therapeutics (NASDAQ: MCRB) announced that CEO Eric Shaff will participate in a panel at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 10:30 a.m. ET. An audio webcast of the discussion will be available on their website, with a replay accessible for 21 days post-event.

Seres is recognized for its pioneering work in microbiome therapeutics, highlighted by its SER-109 program, which has achieved positive clinical results for treating C. difficile infections. Additionally, SER-301 and SER-155 are in Phase 1b studies targeting ulcerative colitis and infection prevention in medically compromised patients.